Do lipid-lowering drugs cause erectile dysfunction? A systematic review

被引:81
作者
Rizvi, K [1 ]
Hampson, JP [1 ]
Harvey, JN [1 ]
机构
[1] Univ Wales Coll Med, Wrexham Acad Unit, Wrexham, Wales
关键词
adverse drug reactions; erectile dysfunction; fibrates; statins;
D O I
10.1093/fampra/19.1.95
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Erectile dysfunction (ED) is common although under-reported by patients. Along with the better known causes of ED, drug-induced impotence needs to be considered as a cause of this symptom. Lipid-lowering drugs have been prescribed increasingly. Their relationship to ED is controversial. Objectives. Our aim was to clarify the relationship between lipid-lowering therapy and ED. A secondary aim was to assess the value of the sytematic review procedure in the area of adverse drug reactions. Methods. A systematic review was carried out using computerized biomedical databases and Internet sources. Terms denoting ED were linked with terms referring to lipid-lowering drugs. Information was also sought from regulatory agencies. Results. A significant literature was identified, much from obscure sources, which included case reports, review articles, and information from clinical trials and from regulatory agencies. Information from all of these sources identified fibrates as a source of ED. A substantial number of cases of ED associated with statin usage have been reported to regulatory agencies. Case reports and clinical trial evidence supported the suggestion that statins can also cause ED. Some information on possible mechanisms was obtained, but the mechanism remains uncertain. Conclusions. The systematic review procedure was applied successfully to collect evidence suggesting that both statins and fibrates may cause ED. More numerous reports to regulatory agencies complemented more detailed information from case reports to provide a new perspective on a common area of prescribing.
引用
收藏
页码:95 / 98
页数:4
相关论文
共 35 条
[1]  
*ABPI, ABPI COMP DAT SHEETS
[2]  
*ADV DRUG REACT AD, 1995, AUST ADVERSE DRUG RE, V14, P10
[3]   Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment [J].
Azzarito, C ;
Boiardi, L ;
Vergoni, W ;
Zini, M ;
Portioli, I .
HORMONE AND METABOLIC RESEARCH, 1996, 28 (04) :193-198
[4]   GEMFIBROZIL-INDUCED IMPOTENCE [J].
BAIN, SC ;
LEMON, M ;
JONES, AF .
LANCET, 1990, 336 (8727) :1389-1389
[5]   SEXUAL DYSFUNCTION AFTER GEMFIBROZIL [J].
BHARANI, A .
BRITISH MEDICAL JOURNAL, 1992, 305 (6855) :693-693
[6]   REVIEW OF EUROPEAN CLINICAL-EXPERIENCE WITH FENOFIBRATE [J].
BLANE, GF .
CARDIOLOGY, 1989, 76 :1-13
[7]   HMG-CoA reductase inhibitor-induced impotence - Comment [J].
Boyd, IW .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (10) :1199-1199
[8]   Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction [J].
Bruckert, E ;
Giral, P ;
Heshmati, HM ;
Turpin, G .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1996, 21 (02) :89-94
[9]  
BURNSCOX N, 1997, PRESCRIBER 0305, P77
[10]   LONG-TERM ENDOCRINE FUNCTION IN HYPERCHOLESTEROLEMIC PATIENTS TREATED WITH PRAVASTATIN, A NEW 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE INHIBITOR [J].
DOBS, AS ;
SARMA, PS ;
SCHTEINGART, D .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (09) :1146-1152